Chemistry:Itolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD6 |
| Clinical data | |
| Trade names | Alzumab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Itolizumab (INN, trade name Alzumab) is a 'first in class' humanized IgG1 monoclonal antibody developed by Biocon[1] and the Center of Molecular Immunology (CIM), Havana.[2]
Mechanism of action
It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[3]
Clinical trials
A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[4]
Applications
Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013.[1][5]
In July 2020, Biocon received authorization in India for its use in the treatment of COVID-19.[6]
References
- ↑ 1.0 1.1 "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. (United Kingdom) 31 (12): pp. 1062–3. December 2013. http://www.nature.com/nbt/journal/v31/n12/full/nbt1213-1062b.html.
- ↑ "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020. https://theprint.in/health/india-prepares-to-test-itolizumab-the-drug-credited-for-lowering-covid-mortality-in-cuba/431666/.
- ↑ "Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis". Biocon Limited. 8 January 2013. http://www.biocon.com/docs/PR_080113.pdf?subLink=news.
- ↑ "Biocon's test shows positive results for Itolizumab". 10 January 2012. https://www.thehindubusinessline.com/companies/biocons-test-shows-positive-results-for-itolizumab/article23068151.ece.
- ↑ "Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization". Pharmabiz.com (India: Saffron Media). January 8, 2013. http://www.pharmabiz.com/NewsDetails.aspx?aid=73075&sid=2.
- ↑ "Biocon's Itolizumab approved for COVID-19 treatment: All you need to know". https://economictimes.indiatimes.com/industry/healthcare/biotech/biocons-itolizumab-approved-for-covid-19-treatment-all-you-need-to-know/videoshow/76943684.cms.
 |  |
